Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SRRK 
Scholar Rock Holding Corp (SRRK)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: SRRK (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $50.11
1 Year Target Price $50.11
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 159.1% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.24B USD | Price to earnings Ratio - | 1Y Target Price 50.11 |
Price to earnings Ratio - | 1Y Target Price 50.11 | ||
Volume (30-day avg) 10 | Beta 0.37 | 52 Weeks Range 6.76 - 46.98 | Updated Date 09/15/2025 |
52 Weeks Range 6.76 - 46.98 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -71.29% | Return on Equity (TTM) -172.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2810866482 | Price to Sales(TTM) 13.14 |
Enterprise Value 2810866482 | Price to Sales(TTM) 13.14 | ||
Enterprise Value to Revenue 8.22 | Enterprise Value to EBITDA -2.08 | Shares Outstanding 96127296 | Shares Floating 80447947 |
Shares Outstanding 96127296 | Shares Floating 80447947 | ||
Percent Insiders 4.3 | Percent Institutions 120.43 |
Upturn AI SWOT
Scholar Rock Holding Corp
Company Overview
History and Background
Scholar Rock Holding Corp. was founded in 2012 and is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a key role. The company leverages its expertise in growth factor biology to develop novel therapies for fibrosis, muscular diseases, and cancer.
Core Business Areas
- SRK-015 Program: SRK-015 is a selective inhibitor of myostatin activation and is being developed for the treatment of spinal muscular atrophy (SMA). This program represents a significant part of Scholar Rock's pipeline and focuses on addressing muscle weakness and atrophy associated with SMA.
- SRK-181 Program: SRK-181 is a selective inhibitor of latent transforming growth factor beta 1 (TGFu03b21) activation and is being developed to overcome resistance to checkpoint inhibitors in cancer. This program is designed to enhance the efficacy of immunotherapies by targeting TGFu03b21 signaling in the tumor microenvironment.
- SRK-439 Program: SRK-439 is a selective inhibitor of latent transforming growth factor beta (TGFu03b2) activation and is being developed for the treatment of fibrotic diseases. This program is focused on targeting diseases characterized by excessive tissue scarring and fibrosis.
Leadership and Structure
The leadership team includes individuals with expertise in drug development, clinical research, and business strategy. Nagesh Mahanthappa is the CEO. The company has a board of directors overseeing its strategic direction and governance.
Top Products and Market Share
Key Offerings
- SRK-015: SRK-015, a myostatin inhibitor for SMA, is Scholar Rock's lead clinical program. While no specific market share data is available yet (as it is still in clinical trials), the SMA market is dominated by Biogen (SPINRAZA), Novartis (ZOLGENSMA), and Roche (Evrysdi). SRK-015 aims to improve muscle function in SMA patients. Competitors include Biogen, Novartis, and Roche.
- SRK-181: SRK-181, a TGFu03b21 inhibitor for cancer immunotherapy, is in early clinical development. Specific market share data is not yet available. Its competitors would include pharmaceutical companies developing similar cancer immunotherapies. Competitors include Merck, Bristol-Myers Squibb, and Roche in the larger immune-oncology space.
- SRK-439: SRK-439, a TGFu03b2 inhibitor for fibrotic diseases, is in early clinical development. Specific market share data is not yet available. Potential competitors would be companies focusing on anti-fibrotic therapies. Competitors include Boehringer Ingelheim and Roche.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and long development timelines. Competition is intense, with numerous companies vying for market share in various therapeutic areas.
Positioning
Scholar Rock positions itself as a leader in growth factor biology, focusing on developing innovative therapies for diseases with unmet medical needs. Its competitive advantage lies in its expertise in targeting specific growth factors and developing selective inhibitors.
Total Addressable Market (TAM)
The combined TAM for SMA, cancer immunotherapies, and fibrotic diseases is estimated to be in the billions of dollars. Scholar Rock is positioned to capture a portion of this market through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform for growth factor inhibition
- Strong expertise in growth factor biology
- Lead clinical program (SRK-015) addressing a significant unmet need in SMA
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Reliance on clinical trial success
- No products currently generating revenue
Opportunities
- Potential for SRK-015 to become a leading therapy for SMA
- Expansion of pipeline through further research and development
- Strategic partnerships and collaborations
- Positive clinical trial results driving investor interest and funding
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- RHHBY
Competitive Landscape
Scholar Rock's advantage lies in its targeted approach to growth factor inhibition. However, it faces competition from larger companies with more resources and established market positions.
Growth Trajectory and Initiatives
Historical Growth: Scholar Rock's historical growth is primarily reflected in its pipeline development and clinical trial progress.
Future Projections: Future growth projections depend on the success of its clinical programs and potential regulatory approvals. Analyst estimates vary depending on the specific program and market conditions.
Recent Initiatives: Recent initiatives include advancing SRK-015 into late-stage clinical trials, expanding its pipeline with new programs, and securing partnerships and collaborations.
Summary
Scholar Rock is a clinical-stage biopharmaceutical company with a promising pipeline focused on growth factor biology. SRK-015 for SMA represents a significant opportunity if clinical trials are successful. The company is relatively small compared to major players, so success is reliant on clinical progress and partnerships. Failure in trials or regulatory hurdles poses a risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scholar Rock Holding Corp
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2018-05-24 | CEO & Chairman of the Board Mr. David L. Hallal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.scholarrock.com |
Full time employees 128 | Website https://www.scholarrock.com | ||
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.